Cargando…

Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319548/
https://www.ncbi.nlm.nih.gov/pubmed/31305738
http://dx.doi.org/10.1097/MD.0000000000006193
_version_ 1782509402580844544
collection PubMed
description
format Online
Article
Text
id pubmed-5319548
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-53195482017-03-02 Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum Medicine (Baltimore) Erratum Wolters Kluwer Health 2017-02-17 /pmc/articles/PMC5319548/ /pubmed/31305738 http://dx.doi.org/10.1097/MD.0000000000006193 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Erratum
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
title Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
title_full Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
title_fullStr Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
title_full_unstemmed Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
title_short Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
title_sort assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: erratum
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319548/
https://www.ncbi.nlm.nih.gov/pubmed/31305738
http://dx.doi.org/10.1097/MD.0000000000006193